Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

WARRINGTON, PA — Windtree Therapeutics, Inc. has announced a new patent application for istaroxime derivatives, aimed at preventing or reducing the risk of acute myocardial arrhythmia. The filing ...

Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic shock. Johnson & Johnson MedTech, the global leader in heart recovery, announced ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...

Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

The article "Improving Cardiogenic Shock Team Activation ... and other clinicians know when to escalate a patient's treatment to the shock pathway." Educating the nursing team was one of the ...

Syrian rebels against the country’s President Bashar Al-Assad advanced toward one of the largest cities in the country — the first time since 2016 — following a shock offensive launched by ...

The advance on Aleppo followed a shock offensive launched by insurgents Wednesday, as thousands of fighters swept through villages and towns in Syria’s northwestern countryside. Residents fled ...

Sex does not affect the prognosis once cardiogenic shock is established in patients with cardiogenic shock due to Takotsubo syndrome. Management and treatment of cardiogenic shock due to Takotsubo ...

Sex‐related differences in Takotsubo syndrome have been described, but no information is available in patients who develop cardiogenic shock. Cardiogenic shock due to Takotsubo syndrome has high short ...

Conventional radiation treatment might slow their growth, but Carter was certain to die. Then his doctors gave him pembrolizumab (Keytruda), a new immunotherapy medication that could spur a ...